Immupharma PLC - Conversion of Convertible Security
("ImmuPharma" or the "Company")
Conversion of Convertible Security
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that
New Ordinary Shares and Admission
The New Ordinary Shares will be issued credited as fully paid and will rank pari passu in all respects with the Company's existing issued ordinary shares.
An application will be made for the New ordinary Shares to be admitted to trading on the AIM market of the
The New Ordinary Shares represent 0.43% of the Company's enlarged issued share capital.
Total Shares in Issue
For the purposes of the Disclosure Guidance and Transparency Rules of the
This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.
The allotment of the New Ordinary Shares is being made pursuant to existing authorities to allot shares and other relevant securities and to disapply pre-emption rights under section 551 of the Companies Act 2006, which the Directors were given at the Company's Annual General Meeting held on
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Subscription with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this Announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.
For further information please contact:
Notes to Editors
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
Quick facts: ImmuPharma PLC
Market Cap: £28.1 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE